The present disclosure relates to, among other things, heart valves, and associated apparatuses and methods of use, manufacture and treatment.
The transport of vital fluids in the human body is largely regulated by valves. Physiological valves are designed to prevent the backflow of bodily fluids, such as blood, lymph, urine, bile, etc., thereby keeping the body's fluid dynamics unidirectional for proper homeostasis. For example, venous valves maintain the upward flow of blood, particularly from the lower extremities, back toward the heart, while lymphatic valves prevent the backflow of lymph within the lymph vessels, particularly those of the limbs.
A human heart includes four cardiac valves that determine the pathway of blood flow through the heart: the mitral valve, the tricuspid valve, the aortic valve, and the pulmonary valve. The mitral and tricuspid valves are atrioventricular valves, which are between the atria and the ventricles, while the aortic and pulmonary valves are semilunar valves, which are in the arteries leaving the heart.
Because of their common function, valves share certain anatomical features despite variations in relative size. Cardiac valves are among the largest valves in the body with diameters that may exceed 30 mm, while valves of smaller veins may have diameters no larger than a fraction of a millimeter. Regardless of their size, however, some physiological valves are situated in specialized anatomical structures known as sinuses. Valve sinuses can be described as dilations or bulges in the vessel wall that houses the valve. The geometry of the sinus has a function in the operation and fluid dynamics of the valve. One function is to guide fluid flow so as to create eddy currents that prevent the valve leaflets from adhering to the wall of the vessel at the peak of flow velocity, such as during systole. Another function of the sinus geometry is to generate currents that facilitate the precise closing of the leaflets at the beginning of backflow pressure. The sinus geometry is also important in reducing the stress exerted by differential fluid flow pressure on the valve leaflets or cusps as they open and close.
Sinuses of the pulmonary trunk comprise the space at the origin of the pulmonary trunk between the dilated wall of the vessel and each cusp of the pulmonic valve. Aortic sinuses or Valsalva sinuses comprise the space between the superior aspect of each cusp of the aortic valve and the dilated portion of the wall of the ascending aorta, immediately above each cusp. Thus, for example, eddy currents occurring within sinuses of Valsalva in the natural aortic root have been shown to be important in creating smooth, gradual and gentle closure of the aortic valve at the end of systole. Blood is permitted to travel along the curved contour of the sinus and onto the valve leaflets to effect their closure, thereby reducing the pressure that would otherwise be exerted by direct fluid flow onto the valve leaflets. The sinuses of Valsalva also contain the coronary ostia, which are outflow openings of the arteries that feed the heart muscle. When valve sinuses contain such outflow openings, they serve the additional purpose of providing blood flow to such vessels throughout the cardiac cycle.
When valves exhibit abnormal anatomy and function as a result of valve disease or injury, the unidirectional flow of the physiological fluid they are designed to regulate is disrupted, resulting in increased hydrostatic pressure. For example, venous valvular dysfunction leads to blood flowing back and pooling in the lower legs, resulting in pain, swelling and edema, changes in skin color, and skin ulcerations that can be extremely difficult to treat. Lymphatic valve insufficiency can result in lymphedema with tissue fibrosis and gross distention of the affected body part. Cardiac valvular disease may lead to pulmonary hypertension and edema, atrial fibrillation, and right heart failure in the case of mitral and tricuspid valve stenosis; or pulmonary congestion, left ventricular contractile impairment and congestive heart failure in the case of mitral regurgitation and aortic stenosis. Regardless of their etiology, all valvular diseases result in either stenosis, in which the valve does not open properly, impeding fluid flow across it and causing a rise in fluid pressure, or insufficiency/regurgitation, in which the valve does not close properly and the fluid leaks back across the valve, creating backflow. Some valves are afflicted with both stenosis and insufficiency, in which case the valve neither opens fully nor closes completely.
Because of the potential severity of the clinical consequences of valve disease, numerous surgical techniques have been developed to repair a diseased or damaged heart valve. For example, these surgical techniques may include annuloplasty (contracting the valve annulus), quadrangular resection (narrowing the valve leaflets), commissurotomy (cutting the valve commissures to separate the valve leaflets), or decalcification of valve and annulus tissue. Alternatively, the diseased heart valve may be replaced by a prosthetic valve. Where replacement of a heart valve is indicated, the dysfunctional valve is typically removed and replaced with either a mechanical or tissue valve.
In the past, one common procedure has been an open-heart type procedure. However, open-heart valve repair or replacement surgery is a long and tedious procedure and involves a gross thoracotomy, usually in the form of a median sternotomy. In this procedure, a saw or other cutting instrument is used to cut the sternum longitudinally and the two opposing halves of the anterior or ventral portion of the rib cage are spread apart. A large opening into the thoracic cavity is thus created, through which the surgeon may directly visualize and operate upon the heart and other thoracic contents. The patient must typically be placed on cardiopulmonary bypass for the duration of the surgery.
Minimally invasive valve replacement procedures have emerged as an alternative to open-chest surgery. Minimally invasive medical procedures may be considered as procedures that are carried out by entering the body through the skin or through a body cavity or anatomical opening, while minimizing damage to these structures. Two types of minimally invasive valve procedures that have emerged are percutaneous valve procedures and trans-apical valve procedures. Percutaneous valve procedures pertain to making small incisions in the skin to allow direct access to peripheral vessels or body channels to insert catheters. Trans-apical valve procedures pertain to making a small incision in or near the apex of a heart to allow valve access.
Traditionally, surgical heart valves have been implanted with a multitude of sutures, so placing the valve at the correct depth was readily accomplished by tactile means. For sutureless valves, such tactile feedback does not exist. Accordingly, alternatives for ensuring proper depth of an implant of sutureless valves would be desirable.
Additionally, ensuring proper orientation of a valve apparatus is fairly routine heart valves anchored via sutures. However, with heart valves that are expandable and initially implanted in a collapsed configuration, ensuring proper orientation can be more challenging.
Described herein are, among other things, prosthetic heart valves having visible markings configured to be aligned with anatomical structures of a native valve, such as an annulus or a commissure. The markings facilitate accurate implantation of the prosthetic valves at a proper depth or in a proper orientation.
In some embodiments, a device configured to be implanted in a valve of a subject is described. The valve includes an annulus. The device comprises a frame having an annular portion configured to be aligned with the annulus of the native valve and a visible circumferential marking positioned around the annular portion of the frame.
The frame, in some embodiments, is expandable from a collapsed configuration to an expanded configuration. In the expanded configuration, the annular portion of the frame is configured to engage the annulus of the native valve. The frame may be configured to be at least partially collapsed from the expanded configuration to an at least partially collapsed configuration such that the frame can be repositioned during an implant procedure if the visible circumferential marking is not aligned with the annulus of the native valve.
The frame, in some embodiments, is expandable from a collapsed configuration to a partially expanded configuration. When the frame is in the partially expanded configuration, the device is configured such that circumferential marking is visible when aligned with the annulus of the native valve.
In some embodiments, the frame has a flange positioned superior to the annular portion when implanted, wherein the flange is compressible and expandable. The flange may be a part of a concave-shaped portion configured to anchor the device around the annulus of the native valve.
In various embodiments, the device includes a skirt disposed over at least a portion of the frame. The visible circumferential marking may be disposed on the skirt.
In some embodiments, the device further includes a second visible circumferential marking positioned around the frame at a location that, when implanted, is superior to the first visible circumferential marking. The second circumferential marking indicates a position to which a sheath of a delivery system is to be withdrawn during a part of an implant procedure in which the device is being positioned within the native valve.
In some embodiments, which may be the same or different than the embodiments where the device includes the visible circumferential marking, a device includes a frame that has a longitudinal portion configured to be aligned with a commissure of the native valve. The device further comprises one or more visible commissural alignment markings positioned to indicate at least a portion of the longitudinal portion of the frame. The device, in some embodiments includes a skirt disposed about at least a portion of the frame. The one or more visible commissural alignment markings may be disposed on the skirt.
In various embodiments, the device is a prosthetic heart valve. In some embodiments the prosthetic heart valve is a sutureless prosthetic heart valve.
In embodiments described herein, a method for implanting a device in a valve of a subject is described. A portion of the device is configured to be aligned with an annulus of the valve. The device has a visible circumferential marking configured to be aligned with the valve annulus. In some embodiments, the method may include inserting at least a portion of the device in a valve sinus, and aligning a visible circumferential marking with the valve annulus. In some embodiments, the device is compressible and expandable, and inserting the device in a native valve comprises inserting the device in an at least partially compressed configuration. The method in such embodiments may further comprise expanding the device, or allowing the device to expand, when the visible circumferential marking is aligned with the native valve annulus. In some embodiments, the device comprises a second visible circumferential marking that when implanted is superior to the first visible circumferential marking. In such embodiments, the method may further include retracting a retention sheath about the device until the second circumferential marking is visible to allow the device to partially expand prior to aligning the first circumferential marking with the native valve annulus. The method may further include completely retracting the sheath about the device when the first visible circumferential marking is aligned with the annulus to allow the device to expand and engage the native valve annulus.
Advantages of one or more of the various embodiments presented herein over prior devices for implanting in a valve of a patient, such as prosthetic heart valves, and associated methods will be readily apparent to those of skill in the art based on the following detailed description when read in conjunction with the accompanying drawings.
The schematic drawings in are not necessarily to scale. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar.
The present disclosure relates to, among other things, devices for implantation in a valve, such as heart valves, and methods, systems, and devices associated therewith. The devices described herein may be particularly useful where tactile feedback of valve positioning is not possible or impracticable, such as when implanting sutureless prosthetic heart valve devices.
In various embodiments, the implantable devices described herein have visible markings configured to be aligned with anatomical structures of a valve, such as an annulus or a commissure. The markings facilitate accurate implantation of the prosthetic valves at a proper depth or in a proper orientation.
Prior to describing devices with such markings, a general description of heart valve device components and heart valve anatomy is provided with regard to
One consideration in the design of valve replacement systems and devices is the architecture of the valve to be replaced. For example, mitral and tricuspid heart valves do not have valve sinuses whereas aortic and pulmonic heart valves have valve sinuses. Valve sinuses 12 are dilations of the vessel wall that surround the natural valve leaflets. Typically in the aortic valve, each natural valve leaflet has a separate sinus bulge 12 or cavity that allows for maximal opening of the leaflet at peak flow without permitting contact between the leaflet and the vessel wall. As illustrated in
Replacement valve 22 illustrated in
The valve replacement systems and devices described herein are not limited, however, to the specific valve illustrated in
Valve leaflets 33 may be constructed of any suitable material, including but not limited to polymeric materials, metallic materials, or tissue-engineered materials. For example, bovine, porcine, equine, ovine, or other suitable animal tissues may be used to construct valve leaflets. In some embodiments, valve leaflets may be constructed of or formed from material obtained from, for example, heart valves, aortic roots, aortic walls, aortic leaflets, pericardial tissue, blood vessels, intestinal submucosal tissue, umbilical tissue and the like from humans or animals. In some embodiments, valve leaflets may be constructed of expanded polytetrafluoroethylene (ePTFE), equine pericardium, bovine pericardium, or native porcine valve leaflets similar to currently available bioprosthetic aortic valves. Other materials may prove suitable as will be appreciated by one skilled in the art.
In some embodiments, valve frame 24 has a generally tubular configuration within which replacement valve 22 may be secured, and includes inflow rim 41, support posts 42 and outflow rim 43. Replacement valve 22 may be secured at the proximal inflow end 31 by attachment to inflow rim 41 of support structure 24 and at the distal outflow end 32 via commissural tabs 35 that are threaded through axially extending slots 44, which are formed in support posts 42 that extend longitudinally from inflow rim 41 to outflow rim 43 of valve support structure 24. Thus, distal ends 45 of support posts 42 contact outflow rim 43 of valve support structure 24, whereas proximal ends 46 of support posts 42 contact inflow rim 41 of valve support structure 24.
In the embodiment shown in
In the embodiment of valve support structure 24 illustrated in
Both inflow rim 41 and outflow rim 43 of valve support structure 24 are formed with an undulating or zigzag configuration. In various embodiments of valve support structures, inflow rim 41 may have a shorter or longer wavelength (i.e., circumferential dimension from peak to peak) or a lesser or greater wave height (i.e., axial dimension from peak to peak) than outflow rim 43. The wavelengths and wave heights of inflow rim 41 and outflow rim 43 may be selected to ensure uniform compression and expansion of valve support structure 24 without substantial distortion. The wavelength of inflow rim 41 is further selected to support the geometry of the inflow end of the valve attached thereto, such as the scalloped inflow end 31 of replacement valve 22 shown in
Support posts 42 further comprise triangular shaped elements 52 extending on each side of proximal end 46 of the support post. Triangular shaped elements 52 may be designed to serve as attachments sites for valve cuff 26 and may be designed in different shapes without losing their function. Thus, the particular design of elements 52 shown in
The number of support posts 42 generally ranges from two to four, and generally depends on the number of commissures and leaflets present in the replacement valve 22. Thus, valve support structure 24 may comprise three support posts for a tri-leaflet replacement valve 22. Support posts 32 of valve frame 24 may be structured to generally coincide with the natural commissures of the native valve being replaced.
Valve frame 24 may be formed from any suitable material including, but not limited to, stainless steel or nitinol. The particular material selected for valve support structure 24 may be determined based upon whether the support structure is self-expanding or non-self-expanding. For example, preferable materials for self-expanding support structures include shape memory materials, such as nitinol.
The positioning of replacement valve 22 internally to frame 24 with only commissural mounting tabs 35 of replacement valve 22 contacting support posts 42 at the distal outflow end 32 of the valve, while the proximal inflow end 31 of the valve is separated from inflow rim 41 of valve support structure 24 by valve cuff 26, ensures that no part of replacement valve 22 is contacted by frame 24 during operation of valve 22, thereby eliminating wear on valve 22 that may be otherwise result from contact with mechanical elements.
As shown in
Skirt 60 of valve cuff 26 is designed to provide numerous benefits when used in conjunction with a replacement valve such as replacement valve 22. First, skirt 60 functions to protect the proximal inflow end 31 of replacement valve 22 from irregularities of a valve annulus such that, for example, calcification remnants or valve remnants left behind after a native valve removal procedure do not come into contact with any portion of replacement valve 22. If otherwise allowed to contact replacement valve 22, these remnants impose a risk of damage to the valve. Second, when positioned adjacent a native valve annulus, skirt 60 provides another source of valve sealing, and also assists valve cuff 26 to conform to irregularities of the native valve annulus. Third, once valve cuff 26 is positioned adjacent a native valve annulus, skirt 60 allows tissue ingrowth into the valve cuff. Such tissue ingrowth not only improves the seal provided by valve cuff 26, but also helps to anchor the valve cuff to the native valve annulus and minimize migration of replacement valve system 20 after implantation. Skirt 60 of valve cuff 26 may provide addition benefits other than those previously discussed as will be appreciated by those skilled in the art.
As illustrated in
Flange 62 of valve cuff 26 is structured for forming a seal between the proximal inflow end 31 of replacement valve 22 and the annulus of the native valve site. In some embodiments, if one or more native valve structures are removed from a patient's body prior to implantation of replacement valve system 20, irregularities may exist around the annulus of the native valve site. These irregularities may be the result of, for example, natural calcifications or valve remnants left over from extraction of the native valve. Irregularities around the annulus can be problematic because they can contribute to paravalvular leakage.
In the past when irregularities were present, it was difficult to maintain a tight seal between the native valve annulus and the replacement valve. However, flange 62 of valve cuff 26 is structured to conform to irregularities around the native valve annulus, thus improving the seal between replacement valve 22 and the native valve annulus. As a result, paravalvular leakage around the replacement valve may be reduced or eliminated.
In some embodiments, an adhesive may be applied to valve cuff 26 prior to implantation within a native valve annulus. For example, any suitable biocompatible adhesive may be applied to the outer surfaces of skirt 60 and flange 62 to help seal valve cuff 26 to the surrounding tissue of the valve annulus. While not a necessary component, biocompatible adhesives may help to provide a tighter seal in order to further reduce paravalvular leakage.
In other embodiments, the flange 62 valve cuff 26 may be constructed with a memory shaped or deformable material disposed within the flange that helps to create a tight seal with the native valve annulus. In particular, the memory shaped or deformable material may be structured to expand once valve cuff 26 is properly positioned at the implantation site. This type of valve cuff flange may be utilized regardless of whether the valve support structure is of the self-expanding or non-self-expanding type.
In some embodiments, both skirt 60 and flange 62 of valve cuff 26 can be formed from a cloth or fabric material. The fabric may comprise any suitable material including, but not limited to, woven polyester such as polyethylene terepthalate, polytetrafluoroethylene (PTFE), or other biocompatible material.
In one exemplary embodiment of assembling valve replacement system 20, skirt 60 and flange 62 are formed as separate components that are coupled together in order to form valve cuff 26. In particular, skirt 60 may initially be positioned around and coupled to valve support frame 24 in any suitable manner, such as by suturing. For example, each skirt attachment portion 63 may be wrapped around a corresponding support post 42 of valve frame 24. Skirt attachment portions 63 may then, for example, be sutured to triangular shaped attachment sites 52 near the proximal ends 46 of each of the support posts 42. Then, flange 62 may be positioned at the desired position around skirt 60 and coupled to the skirt by any suitable means, such as by suturing. Next, replacement valve 22 may be positioned within the inner lumen of frame 24, inserting commissural tab portions 35 of replacement valve 22 through corresponding axially extending slots 44 in support posts 42. Skirt 60 of valve cuff 26, which is positioned circumferentially around inflow rim 41 of frame 24, may then be wrapped around the proximal inflow end 31 of replacement valve 22 and attached to the valve with, for example, sutures. Once attached, skirt 60 and flange 62 are structured to create tight, gasket-like sealing surfaces between replacement valve 22 and the native valve annulus. The foregoing represents only one exemplary embodiment of a method of assembling a valve replacement system in accordance with the present disclosure. Thus, modifications may be made to the number and order of steps as will be appreciate by one skilled in the art.
Referring now to
Frame 24 has a generally tubular configuration within which a replacement valve may be secured, and includes inflow rim 41, support posts 42 and outflow rim 43. A replacement valve may be secured at the proximal inflow end 31 by attachment to inflow rim 41 of support frame 24 and at the distal outflow end 32 via commissural tabs 35 that are threaded through axially extending slots 44, which are formed in support posts 42 that extend longitudinally from inflow rim 41 to outflow rim 43 of valve support structure 24. Thus, distal ends 45 of support posts 42 contact outflow rim 43 of valve support structure 24, whereas proximal ends 46 of support posts 42 contact inflow rim 41 of frame 24.
As shown in
The inflow rim 41 optionally includes finger-like elements 53 positioned at which distal and proximal inflow wire rings 49, 51 connect and extend in an axial direction therefrom. Finger-like elements 53 are designed to lend additional support to fabric that may cover inflow rim 41 to anchor the fabric and permit tissue ingrowth.
In the embodiment of support frame 24 illustrated in
Both inflow rim 41 and outflow rim 43 of frame 24 may be formed with an undulating or sinusoidal wave-like configurations. In various embodiments of valve support structures, inflow rim 41 may have a shorter or longer wavelength (i.e., circumferential dimension from peak to peak) or a lesser or greater wave height (i.e., axial dimension from peak to peak) than outflow rim 43. The wavelengths and wave heights of inflow rim 41 and outflow rim 43 may be selected to ensure uniform compression and expansion of support frame 24 without substantial distortion. The wavelength of inflow rim 41 may be further selected to support the geometry of the inflow end of the valve attached thereto, such as the scalloped inflow end 31 of replacement valve 22 shown in
In the embodiment depicted in
The number of support posts 42, if present, generally ranges from two to four, depending on the number of commissural posts present in the valve sinus. Thus, in some embodiments, valve support structure 24 comprises three support posts for a tri-leaflet replacement valve with a native valve that features three natural commissures. Support posts 42, if present, of frame 24 may be structured to generally coincide with the natural commissures of a native valve.
Turning now to
The concave landing zone 61 substantially prevents paravalvular leakage. Paravalvular leakage may be reduced by ensuring the inflow rim 41 is substantially secured proximally and distally of the annulus, hence forming a tight seal. Concave landing zone 60 allows the surgeon to easily place the bioprosthetic heart valve in the annulus thus minimizing patient time spent in surgery.
Although the above disclosure focused on a tri-leaflet replacement valve system 20, valve cuffs in accordance with the present disclosure may be used in conjunction with any type of replacement valve of generally similar structure, including but not limited to the heart valves disclosed in U.S. application Ser. No. 10/680,071, U.S. application Ser. No. 11/471,092, and U.S. application Ser. No. 11/489,663, all incorporated herein in their entirety to the extent that they do not conflict with the disclosure presented herein. Therefore, the valve cuff concepts disclosed herein may be applied to valve cuffs structured to function with many other types of replacement valves having any number of leaflets without departing from the spirit and scope of the present disclosure.
Furthermore, although the above disclosure focuses on frame 24 having an inflow rim 41, an outflow rim 43, and three support posts 42, this particular valve support structure was described merely for purposes of example and not limitation. Thus, valve cuffs in accordance with the present disclosure may be used in conjunction with any generally tubular, stent-like valve support structure, as will be appreciated by one skilled in the art.
Additional designs of prosthetic heart valves for which the markings described below may be beneficial include those designs disclosed in U.S. Provisional Patent Application No. 61/819,486 filed on May 3, 2013, and those disclosed in U.S. patent application Ser. No. ______, entitled PROSTHETIC VALVES AND ASSOCIATED APPARATUSES, SYSTEMS AND METHODS, having attorney docket number C00005661.USU3, filed on the same day as the present application, which patent applications are each hereby incorporated herein by reference in their respective entireties to the extent that they do not conflict with the disclosure presented herein.
In embodiments, replacement valve systems described herein are sutureless valve systems. Of course, sutures may be used with such systems. Advantages to sutureless replacement valve systems include shorter implant procedure times and less invasive implantation. Some disadvantages or perceived disadvantages with current sutureless valve systems include potential increased risk of paravalvular leakage (PVL) and potential lack of durability. The designs presented herein preferably address one or more of the disadvantages or perceived disadvantages of current sutureless valve designs.
Traditionally, surgical heart valves have been implanted with a multitude of sutures, so placing the valve at the correct depth was readily accomplished by tactile means. For sutureless valves, such tactile feedback does not exist. Accordingly, alternatives for ensuring proper depth of an implant of sutureless valves would be desirable.
Additionally, ensuring proper orientation of a valve apparatus is fairly routine heart valves anchored via sutures. However, with heart valves that are expandable and initially implanted in a collapsed configuration, ensuring proper orientation can be more challenging.
In embodiments described herein, a replacement valve system 20 may include one or more markings to provide visible feedback to an implanter that the replacement valve system 20 is implanted in a desired location, position, or orientation, such as at a proper depth. In some embodiments, the marking comprises a marking around a circumference of the valve apparatus 20. In some embodiments, the marking comprises a circumferential marking at a location of the valve apparatus to be aligned with one or more structures of a patient's anatomy such as one or more structures related to a patient's valve that requires replacement.
In embodiments, described herein, a heart valve apparatus includes a marking to provide visible feedback to an implanter that correct rotational orientation of the valve apparatus is achieved. In embodiments, the marking comprises a marking along at least a portion of the length of the valve apparatus. In embodiments, the marking is configured to be aligned with a commissure of the patient's valve.
With the above general description in mind, reference is now made to
Circumferential marking 61 may be in the form of a circumferential line, which may be solid or dashed. Circumferential marking 61 may be in the form of a transition edge, where the skirt is one color or pattern below the edge and another color or pattern above the edge. Circumferential marking 61 may be formed from die, ink, thread, band or ribbon, or the like. Circumferential marking 61 may be formed from a transition between two types of materials. For example, the “bottom half” may be formed from one material and the “top half” may be formed from another material. Any suitable materials may be used to create a demarcation or delineation line, such as fabric, polymer, tissue or the like.
In embodiments, a ribbon may be stitched around the circumference of a skirt to form a circumferential marking. The ribbon or stitching may be colored. The ribbon may be placed on the skirt before or after the skirt is placed on the valve apparatus. The ribbon may be formed of any suitable material, such as cottony Dacron, cottony II or the like.
In
Commissural-alignment markings 63 may be formed in any suitable manner: e.g., die, ink, thread, band or ribbon, or the like. Vertical markings 63 can be of any suitable width, can be solid or dashed, or the like.
Vertical markings 63 may also serve the purpose of identifying where the commissures of the bioprosthesis valve apparatus are located. In this manner the user can check that the bioprosthesis valve apparatus commissures will not block coronary flow.
Also shown in
Referring now to
The valve retention sheath 200 shown in
While the markings depicted in
In one or more embodiments, valve prosthesis may comprise a balloon-expandable, mechanically-expandable, or a self-expandable frame that may be collapsed during delivery and expanded upon deployment within a native valve. The frame may be self-expanding via removal of external compressive forces or expanded using an outward radial force (e.g., balloon or mechanical expansion). In one or more embodiments, valve prosthesis or one or more of its components or portions may be positioned in, positioned through, or positioned adjacent to, for example, a natural valve, a native valve, a synthetic valve, a replacement valve, a tissue valve, a mechanical valve, a mitral valve, an aortic valve, a pulmonary valve, a tricuspid valve, a valve component, a valve annulus, a valve leaflet, chordea, or a valve commissure.
In one or more embodiments, valve prosthesis may be implanted into an annulus of a native cardiac valve via a suitable delivery route or procedure. For example, the valve prosthesis may be delivered through an artery or vein, a femoral artery, a femoral vein, a jugular vein, a subclavian artery, an axillary artery, an aorta, an atrium, or a ventricle. The valve prosthesis may be delivered via a transfemoral, transapical, transseptal, transatrial, transventrical, transaortic, transcatheter, surgical, beating heart, stopped heart, pump-assisted, or a cardiopulmonary bypass procedure.
In one or more embodiments, valve prosthesis or one or more of its components or portions may be delivered, for example, through a thoracotomy, a sternotomy, percutaneously, transvenously, arthroscopically, endoscopically, for example, through a percutaneous port, a stab wound or puncture, through a small incision, for example, in the chest, groin, abdomen, neck, leg, arm, or in combinations thereof.
In certain embodiments, the valve prosthesis is configured for replacing an aortic valve. Alternatively, other shapes are also envisioned to adapt to the specific anatomy of the valve to be replaced (e.g., stented prosthetic heart valves in accordance with the present disclosure can be shaped or sized for replacing a native aortic, mitral, pulmonic or tricuspid valve). In one or more embodiments, valve prosthesis or one or more of its components or portions may comprise, be covered with, be coated with, or be attached or coupled to one or more biocompatible materials or biomaterials, for example, titanium, titanium alloys, Nitinol, TiNi alloys, shape memory alloys, super elastic alloys, aluminum oxide, platinum, platinum alloys, stainless steels, stainless steel alloys, MP35N, elgiloy, haynes 25, stellite, pyrolytic carbon, silver carbon, glassy carbon, polymers or plastics such as polyamides, polycarbonates, polyethers, polyesters, polyolefins including polyethylenes or polypropylenes, polystyrenes, polyurethanes, polyvinylchlorides, polyvinylpyrrolidones, silicone elastomers, fluoropolymers, polyacrylates, polyisoprenes, polytetrafluoroethylenes, polyethylene terephthalates, fabrics such as woven fabrics, nonwoven fabrics, porous fabrics, semi-porous fabrics, nonporous fabrics, Dacron fabrics, polytetrafluoroethylene (PTFE) fabrics, polyethylene terephthalate (PET) fabrics, materials that promote tissue ingrowth, rubber, minerals, ceramics, hydroxapatite, epoxies, human or animal protein or tissue such as collagen, laminin, elastin or fibrin, organic materials such as cellulose, or compressed carbon, or other materials such as glass, and the like. Materials that are not considered biocompatible may be modified to become biocompatible by a number of methods well known in the art. For example, coating a material with a biocompatible coating may enhance the biocompatibility of that material. Biocompatible materials or biomaterials are usually designed and constructed to be placed in or onto tissue of a patient's body or to contact fluid of a patient's body. Ideally, a biocompatible material or biomaterial will not induce undesirable reactions in the body such as blood clotting, tumor formation, allergic reaction, foreign body reaction (rejection) or inflammatory reaction; will have the physical properties such as strength, elasticity, permeability, and flexibility required to function for the intended purpose; may be purified, fabricated and sterilized easily; will substantially maintain its physical properties and function during the time that it remains in contact with tissues or fluids of the body.
There are several contemplated methods for implanting the valve replacement systems described above. In a first method, the patient is placed on cardiopulmonary bypass. A small incision is made on the upper sternum to access the ascending aorta. The aorta is clamped and opened to expose the diseased aortic valve, which is excised. The replacement valve system is then inserted within the aorta under direct vision. The valve cuff coupled to the replacement valve thereafter assists in both fixing the valve to the aortic valve annulus and preventing or reducing paravalvular leakage by forming a tight seal with aortic valve annulus.
In a second method, a self-expanding valve is collapsed and delivered in a collapsed state. Once the valve is properly positioned within the native valve, the valve is deployed, thereby allowing the valve to expand into position with the valve cuff pushing against the valve annulus to form a tight seal. In such an embodiment, the self-expanding valve includes a self-expanding frame that is structured to provide the radial force necessary to push the cuff against the native valve annulus.
In a third method, a non-self-expanding valve is “rolled” up and delivered to the native valve. Once property positioned within the native valve, the valve cuff is pushed against the native valve annulus by “unrolling” the replacement valve.
One skilled in the art will appreciate that although only three replacement valve implantation methods are described herein, numerous other methods are possible and within the intended scope of the present disclosure. Thus, the three exemplary implantation methods are provided for purposes of example and not limitation.
Implant methods, valve delivery systems and associated devices that may be employed with the replacement valve systems described herein are disclosed in U.S. patent application Ser. No. ______, entitled VALVE DELIVERY TOOL, having attorney docket no. C00001363.USU2, filed on the same day as the present application, which application is hereby incorporated herein by reference in its entirety to the extent that it does not conflict with the present disclosure.
All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise.
As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. The term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements.
As used herein, “have”, “having”, “include”, “including”, “comprise”, “comprising” or the like are used in their open ended sense, and generally mean “including, but not limited to”. It will be understood that “consisting essentially of”, “consisting of”, and the like are subsumed in “comprising” and the like. As used herein, “consisting essentially of,” as it relates to a composition, article, system, method or the like, means that the components of the composition, article, system, method or the like are limited to the enumerated components and any other components that do not materially affect the basic and novel characteristic(s) of the composition, article, system, method or the like.
The words “preferred” and “preferably” refer to embodiments of the disclosure that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the disclosure, including the claims.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc. or 10 or less includes 10, 9.4, 7.6, 5, 4.3, 2.9, 1.62, 0.3, etc.). Where a range of values is “up to” a particular value, that value is included within the range.
As used herein, the term “about” encompasses the range of experimental error that occurs in any measurement.
As used herein, “exemplary” means serving as an example and does not necessarily imply that the example is preferable or the best of its kind.
Any patent or non-patent literature, including published patent applications and provisional patent applications, cited herein is hereby incorporated herein by reference in its entirety to the extent that it does not conflict with the disclosure presented herein.
In the detailed description above several specific embodiments of compounds, compositions, articles, systems and methods are disclosed. It is to be understood that other embodiments are contemplated and may be made without departing from the scope or spirit of the present disclosure. The detailed description, therefore, is not to be taken in a limiting sense.
Thus, embodiments of MEDICAL DEVICES FOR IMPLANTING IN A VALVE AND ASSOCIATED METHODS are disclosed. One skilled in the art will appreciate that the heart valves and associated apparatuses, systems and methods described herein can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation.
This application claims the benefit of U.S. Provisional Patent Application No. 61/930,851, filed on Jan. 23, 2014 and U.S. Provisional Patent Application No. 61/819,486 filed on May 3, 2013, each of which Provisional patent applications are hereby incorporated herein by reference in their respective entireties to the extent that they do not conflict with the disclosure presented herein.
Number | Date | Country | |
---|---|---|---|
61930851 | Jan 2014 | US | |
61819486 | May 2013 | US |